PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kral, M.* ; van der Vorst, E.P.C.* ; Surnov, A. ; Weber, C.* ; Döring, Y.*

ILC2-mediated immune crosstalk in chronic (vascular) inflammation.

Front. Immunol. 14:1326440 (2023)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Crosstalk between innate and adaptive immunity is pivotal for an efficient immune response and to maintain immune homeostasis under steady state conditions. As part of the innate immune system, type 2 innate lymphoid cells (ILC2s) have emerged as new important regulators of tissue homeostasis and repair by fine-tuning innate-adaptive immune cell crosstalk. ILC2s mediate either pro- or anti-inflammatory immune responses in a context dependent manner. Inflammation has proven to be a key driver of atherosclerosis, resembling the key underlying pathophysiology of cardiovascular disease (CVD). Notably, numerous studies point towards an atheroprotective role of ILC2s e.g., by mediating secretion of type-II cytokines (IL-5, IL-13, IL-9). Boosting these protective responses may be suitable for promising future therapy, although these protective cues are currently incompletely understood. Additionally, little is known about the mechanisms by which chemokine/chemokine receptor signaling shapes ILC2 functions in vascular inflammation and atherosclerosis. Hence, this review will focus on the latest findings regarding the protective and chemokine/chemokine receptor guided interplay between ILC2s and other immune cells like T and B cells, dendritic cells and macrophages in atherosclerosis. Further, we will elaborate on potential therapeutic implications which result or could be distilled from the dialogue of ILC2s with cells of the immune system in cardiovascular diseases.
Impact Factor
Scopus SNIP
Altmetric
7.300
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Ilc2 ; Atherosclerosis ; Cardiovascular Disease ; Chemokine Receptors ; Inflammation ; Tissue Repair; Innate Lymphoid-cells; Regulatory T-cells; Adipose-tissue; Gene-expression; Type-2 Immunity; Atherosclerosis; Il-33; Receptor; Promotes; Eosinophils
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 1664-3224
e-ISSN 1664-3224
Journal Frontiers in Immunology
Quellenangaben Volume: 14, Issue: , Pages: , Article Number: 1326440 Supplement: ,
Publisher Frontiers
Publishing Place Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland
Reviewing status Peer reviewed
Institute(s) Research Unit Type 1 Diabetes Immunology (TDI)
POF-Topic(s) 30201 - Metabolic Health
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502191-001
Grants Interdisciplinary Center for Clinical Research within the faculty of Medicine at the RWTH Aachen University
Deutsche Forschungsgemeinschaft
DOI 10.3389/fimmu.2023.1326440
WOS ID 001134704500001
Scopus ID 85181223612
PubMed ID 38179045
Erfassungsdatum 2024-01-07
[➜Report correction]